Cancer Heterogeneity and Plasticity ISSN 2818-7792

Cancer Heterogeneity and Plasticity 2024;1(1):0006 | https://doi.org/10.47248/chp2401010006

Perspective Open Access

Developing a novel therapeutic strategy against cancer stem cell heterogeneity and plasticity

Toru Kondo

  • Division of Stem Cell Biology, Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0815, Japan

Academic Editor(s): Dean Tang

Received: Jul 11, 2024 | Accepted: Sep 16, 2024 | Published: Sep 27, 2024

Cite this article: Kondo T. Developing a novel therapeutic strategy against cancer stem cell heterogeneity and plasticity. Cancer Heterog Plast 2024; 1(1):0006. https://doi.org/10.47248/chp2401010006

Abstract

Cancer consists of heterogeneous cells, including cancer stem cells (CSCs), cancer cells, and tumor-associated cells, such as immune cells and vascular cells. Considering that these diverse cell types influence one another directly and indirectly through membrane proteins and secretion factors, such as exosomes and growth factors, the overall heterogeneity affects tumorigenicity and resistance to therapy. This review explores cancer heterogeneity, focusing on CSC heterogeneity, and discussed how the heterogeneity emerges by the intrinsic mechanism and the external factors and affects response to therapy. Additionally, as a potential therapeutic strategy to address this heterogeneity, I propose new Adeno-associated virus carrying a miRNA-dependent CSC eradication system that targets all types of CSCs with minimizing side effects.

Keywords

Glioblasoma (GBM), GBM-initiating cells (GICs), heterogeneity, stem cell factors, microRNA (miR), Adeno-Associated virus (AAV)

Share this article

About Us Journals Join Us Submit Fees Contact